SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to represent SpaceX, with many warning it is a scam while others speculate on its connection to the company's long-rumored IPO. The community conversation is dominated by intense skepticism regarding unauthorized tokens, contrasted with broader market excitement surrounding SpaceX's expected public debut and its potential impact on space-sector stocks.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors highlight its role as an AI-powered infrastructure project on the Base ecosystem, with community members actively discussing its long-term potential as an undervalued asset. The sentiment is fueled by consistent development updates from the team and strong ecosystem volume, leading many to hold through market volatility in anticipation of future price appreciation.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending as investors focus on its U.S.-based ISR production ramp-up, with community discussions highlighting its potential to capture rising demand from AI-driven data center power needs. The stock is seeing heavy attention amid a broader nuclear energy narrative, as market participants monitor institutional accumulation and upcoming earnings in anticipation of a potential sector-wide squeeze.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors weigh the company's aggressive AI and cloud infrastructure pivot against upcoming earnings and high-stakes geopolitical trade talks. While the community is split between bullish sentiment over long-term AI potential and skepticism surrounding recent earnings volatility, attention is heavily focused on whether institutional positioning will trigger a re-rating for the stock.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending as investors monitor institutional accumulation and signs of a potential short squeeze amid anticipation of profitability in the coming quarters. The community is actively discussing the drug's strong prescription growth and its long-term potential as an acquisition target for larger pharmaceutical firms.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is drawing significant market attention as a key retail earnings play, with the community actively debating whether the company's recent turnaround initiatives and leadership changes can justify its year-to-date performance. Investors are closely scrutinizing signs of a rebound in comparable sales and the retailer's ability to navigate persistent consumer spending pressures in a competitive big-box environment.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is seeing significant community interest driven by its strategic acquisition of Covelya Group, which bolsters its subsea technology platform, and heightened geopolitical focus on critical underwater infrastructure protection. Investors are actively discussing the company's long-term defense sector role, its potential for major exchange uplisting, and strong revenue growth outlook.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

Pinduoduo is seeing high volatility as investors balance strong earnings-driven growth potential with significant competitive pressures and ongoing regulatory scrutiny. The community is actively debating the stock's long-term value, with many traders closely monitoring high-volume options activity for signs of a breakout.

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic Plc

Medtronic is trending as investors weigh its potential for growth following the announcement of a planned spin-off of its diabetes business. The market is closely watching this move alongside broader sector rotation, as the company works to improve margins and streamline its portfolio while navigating ongoing scrutiny from activist investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the transaction, the chief operating officer owned 4,517...

Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 4,517 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the sale, the chief operating officer...

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Morgan Stanley upped their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an 'equal weight' rating in a report on Tuesday...

Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00

Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an 'overweight' rating in a research note on Tuesday...

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho

Mizuho increased their target price on Axsome Therapeutics from $228.00 to $310.00 and gave the company an 'outperform' rating in a report on Tuesday...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eighteen h...

<ul class="summary-bullets"><li>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder.</li><li>The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.</li><li>Deutsche Bank analyst David Hoang hiked his price target for Axsome, citing a positive outlook for Auvelity’s commercial launch and growth potential.</li></ul>Axsome Therapeutics Inc. (AXSM) reported a mixed first quarter on Monday, but analysts on Wall Street remain optimistic about the company’s prospects.According to TheFly, Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating. The new price target implies an upside potential of nearly 21% from current levels.<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics shares</a> were up more than 10% in Monday morning’s trade. AXSM was among the top trending tickers on Stocktwits at the time of writing.<h2 class="st-heading-2">Why Is Wall Street Bullish?</h2>Tsai stated that Auvelity’s Q1 sales of $153 million exceeded consensus estimates for major depressive disorder. The analyst believes the 2026 revenue estimate of $805 million for Auvelity is achievable, driven in part by a potential label expansion into Alzheimer’s agitation, which could boost sales in the second half of the year.Auvelity is Axsome’s treatment for agitation associated with dementia due to Alzheimer’s disease. Auvelity received a “clean label” approval from the U.S. Food and Drug Administration (FDA) last week, meaning that Auvelity will not carry a warning for increased risk of death in elderly patients with dementia.According to analysts at TD Cowen, this differentiates Auvelity from the only other approved therapy for ADA, Rexulti.Deutsche Bank analyst David Hoang raised the firm’s price target on Axsome Therapeutics to $281 from $245 and maintained a ‘Buy’ rating. Hoang cited a positive outlook for Auvelity’s commercial launch and growth potential as the reason for the price target hike.H.C. Wainwright analysts raised the firm’s price target on Axsome Therapeutics to $270 from $250 and maintained a ‘Buy’ rating, citing the FDA approval of Auvelity.<h2 class="st-heading-2">What Is Auvelity?</h2>Auvelity is an oral therapy targeting NMDA and sigma-1 receptors, having been approved in the U.S. for major depressive disorder and, more recently, for agitation associated with Alzheimer’s-related dementia.The company stated that about 223,000 prescriptions were written in Q1 2026, up 35% year-on-year and in line with fourth-quarter (Q4) levels. Axsome stated that payer coverage reached roughly 86% overall, including 78% in commercial plans and full coverage in Medicare and Medicaid.Following its FDA approval last week for Alzheimer’s agitation, the drug is set for a commercial launch in June. The company has also completed an expansion of its sales force to around 630 representatives, targeting a wide range of prescribers to support growth in both depression and Alzheimer’s-related use.<h2 class="st-heading-2">Axsome’s Mixed Q1</h2>Axsome Therapeutics’ Q1 results came in mixed on Monday. The company reported a loss of $1.26 per share, while Wall Street expected a loss of $0.86 per share, according to Fiscal.ai data.Axsome’s revenue came in at $191.2 million, edging past Wall Street’s estimates of $190.7 million.According to Koyfin data, the average 12-month price target for AXSM is $235.85, implying an upside of nearly 4% from current levels. Of the 20 analysts covering the stock, 19 have a ‘Buy’ or a ‘Strong Buy’ rating, while one has a ‘Hold’ recommendation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AXSM">Axsome Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘high’ levels at the time of writing.One bullish user expects Auvelity sales to reach at least $1.2 billion by the end of this year.<stembedurl>https://stocktwits.com/Georgejj/message/652182986</stembedurl>Another user thinks that big pharmaceutical companies are more willing than ever to acquire Axsome Therapeutics.<stembedurl>https://stocktwits.com/CloudMatt/message/652181828</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> is up 24% year-to-date and 102% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 27% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fnma-stock-in-focus-mizuho-fannie-mae-best-business-one-could-hope-for/cZQMvMpReJX">Mizuho Believes Fannie Mae Is Among The Best Businesses One Could Hope For — But Not Everyone Agrees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism?

Jefferies analyst Andrew Tsai hiked the firm’s price target for Axsome to $275 from $245 while keeping a ‘Buy’ rating, implying an upside potential of nearly 21% from current levels.

Equity

Axsome Therapeutics Q1 Earnings Call Highlights

Axsome Therapeutics (NASDAQ:AXSM) reported first-quarter 2026 results highlighting strong year-over-year revenue growth, a major new FDA approval for Auvelity, and continued advancement across its neuroscience pipeline. Management also detailed commercial investments to support an upcoming launch in...

Axsome Therapeutics (NASDAQ:AXSM) Reaches New 12-Month High Following Analyst Upgrade

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High After Analyst Upgrade...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Current Price	$227.72
Prev Close	$232.27
Open	$229.71
Dividend Yield	0.00%
50-Day Moving Average	$183.05
Beta	0.74
Avg. Volume	717,490.48
PE Ratio	-60.90

52-Week High	$235.92
52-Week Low	$96.09
Market Capitalization	$11.72B
EPS (Annual)	-$3.68
Price to Book	214.51
Revenue Per Employee	$690,265.95

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News

AXSMAxsome Therapeutics Inc